MOBIC Drug Patent Profile

When do Mobic patents expire, and when can generic versions of Mobic launch?

Mobic is a drug marketed by Boehringer Ingelheim and is included in one NDA.

The generic ingredient in MOBIC is meloxicam. There are twenty-two drug master file entries for this compound. Forty-seven suppliers are listed for this compound. Additional details are available on the meloxicam profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Mobic

A generic version of MOBIC was approved as meloxicam by AVONDALE PHARMS on June 1^st, 2004.

Summary for MOBIC

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	145
Patent Applications:	5,197
Drug Prices:	Drug price information for MOBIC
What excipients (inactive ingredients) are in MOBIC?	MOBIC excipients list
DailyMed Link:	MOBIC at DailyMed

See drug prices for MOBIC

See drug sales revenues for MOBIC

US Patents and Regulatory Information for MOBIC

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Boehringer Ingelheim	MOBIC	meloxicam	TABLET;ORAL	020938-001	Apr 13, 2000		DISCN	Yes	No
Boehringer Ingelheim	MOBIC	meloxicam	TABLET;ORAL	020938-002	Aug 23, 2000		DISCN	Yes	No

EU/EMA Drug Approvals for MOBIC

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Norbrook Laboratories (Ireland) Limited	Loxicom	meloxicam	EMEA/V/C/000141 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders. To reduce postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsAlleviation of inflammation and pain in chronic musculoskeletal disorders in cats. To reduce postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle. For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle. For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation. For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2009-02-10
Le Vet Beheer B.V.	Novaquin	meloxicam	EMEA/V/C/003866 Alleviation of inflammation and relief of pain in both acute and chronic musculo-skeletal disorders in horses.	Authorised	no	no	no	2015-09-08
Le Vet Beheer B.V	Meloxidolor	meloxicam	EMEA/V/C/002590 DogsAlleviation of inflammation and pain in both acute and chronic musculoskeletal disorders.Reduction of postoperative pain and inflammation following orthopaedic and soft-tissue surgery.CatsReduction of postoperative pain after ovariohysterectomy and minor soft-tissue surgery.CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.HorsesFor use in the alleviation of inflammation and relief of pain in both acute and chronic musculoskeletal disorders.For the relief of pain associated with equine colic.	Authorised	yes	no	no	2013-04-22
Boehringer Ingelheim Vetmedica GmbH	Novem	meloxicam	EMEA/V/C/000086 Novem 5-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For the relief of postoperative pain associated with minor soft-tissue surgery such as castration.Novem 20-mg/ml solution for injection for cattle and pigs:CattleFor use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral rehydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.For the relief of postoperative pain following dehorning in calves.PigsFor use in noninfectious locomotor disorders to reduce the symptoms of lameness and inflammation.For adjunctive therapy in the treatment of puerperal septicaemia and toxaemia (mastitis-metritis-agalactia syndrome) with appropriate antibiotic therapy.Novem 40 mg/ml solution for injection for cattle:For use in acute respiratory infection with appropriate antibiotic therapy to reduce clinical signs in cattle.For use in diarrhoea in combination with oral re-hydration therapy to reduce clinical signs in calves of over one week of age and young, non-lactating cattle.For adjunctive therapy in the treatment of acute mastitis, in combination with antibiotic therapy.	Authorised	no	no	no	2004-03-02

MOBIC Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Meloxicam (MOBIC)

Introduction

Meloxicam, marketed under the brand name Mobic, is a nonsteroidal anti-inflammatory drug (NSAID) widely used for the treatment of pain and inflammation associated with arthritis and other inflammatory disorders. Here, we delve into the market dynamics and financial trajectory of meloxicam, highlighting key drivers, challenges, and future projections.

Market Size and Growth

The meloxicam market is experiencing significant growth, driven by several key factors. As of 2023, the market size was valued at USD 2.8 billion and is projected to reach USD 4.2 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 4.5% from 2024 to 2031[1].

Extended Forecast

Looking further ahead, the market is anticipated to expand even more substantially. By 2036, the meloxicam market is expected to reach USD 47 billion, growing at a CAGR of around 5% during the forecast period from 2024 to 2036[4].

Key Drivers of Market Growth

Increasing Prevalence of Arthritis

The rising prevalence of osteoarthritis, rheumatoid arthritis, and juvenile rheumatoid arthritis, particularly among the older population, is a major driver of the meloxicam market. According to the World Health Organization, 60% of those with osteoarthritis are female, and 73% are older than 55[4].

Patient Awareness and Need for Efficient Pain Management

Growing patient awareness and the need for efficient pain management treatments are also significant drivers. The increasing incidence of chronic inflammatory diseases has heightened the demand for long-lasting and effective pain management solutions like meloxicam[1].

Safety Profile and Generic Equivalents

Meloxicam's superior safety profile, with fewer gastrointestinal adverse effects compared to conventional NSAIDs, makes it a preferred option for patients and healthcare professionals. The availability of generic equivalents further enhances market accessibility and affordability[1][2].

Healthcare Infrastructure and Research

The expansion of healthcare infrastructure and ongoing research into new therapeutic uses of meloxicam are additional factors propelling market growth. In regions like North America, increasing healthcare infrastructure and research activities are driving the market forward[4].

Market Segmentation

By Application

The meloxicam market is segmented based on its applications, which include rheumatoid arthritis, osteoarthritis, soft tissue inflammation, traumatic pain, post-operative pain, and other conditions. The osteoarthritis segment is expected to account for the largest revenue share, approximately 40% by 2036[5].

By Product

The market is also segmented by product type, including combination drugs, prescribed drugs, and different dosage forms such as tablets, capsules, and granules. Combination drugs are set to grow significantly due to their ability to treat multiple conditions simultaneously[5].

Geographical Regions

Geographically, the meloxicam market is divided into North America, Europe, Asia-Pacific, South America, and the Middle-East and Africa. North America is anticipated to account for the largest revenue share, driven by a high incidence of arthritis and other chronic pain diseases. The Asia-Pacific region is also expected to see significant growth due to the aging population and favorable reimbursement policies for generic drugs[4].

Financial Projections

Revenue Share

By 2036, the osteoarthritis segment is projected to hold the largest revenue share of 40% in the meloxicam market. The North American market is expected to account for approximately 33% of the total revenue share during the forecast period[4][5].

CAGR and Market Value

The meloxicam market is expected to grow at a CAGR of around 5% from 2024 to 2036, reaching a market value of USD 47 billion by the end of 2036. This growth is substantial, considering the market size was over USD 7 billion in 2023[4].

Challenges and Opportunities

Side Effects and Adverse Reactions

Despite its efficacy, meloxicam is associated with various side effects, including gastrointestinal adverse events, which are the most frequently reported. Other adverse reactions include cardiovascular issues, central and peripheral nervous system disorders, and skin and subcutaneous tissue disorders[2].

Competitive Landscape

The market faces competition from other NSAIDs and combination drugs. However, meloxicam's superior safety profile and the emergence of generic formulations provide it with a competitive edge[1][4].

Research and Development

Ongoing research into new therapeutic uses of meloxicam presents opportunities for market expansion. Innovations in dosage forms and combination therapies could further enhance the market's growth potential[1][4].

Key Takeaways

• Market Growth: The meloxicam market is expected to grow significantly, reaching USD 4.2 billion by 2031 and USD 47 billion by 2036.
• Key Drivers: Increasing prevalence of arthritis, patient awareness, need for efficient pain management, and the availability of generic equivalents.
• Market Segmentation: Segmented by application, product type, and geographical regions, with osteoarthritis and North America being key segments.
• Financial Projections: Expected to grow at a CAGR of around 5% from 2024 to 2036.
• Challenges and Opportunities: Side effects and adverse reactions are challenges, while ongoing research and the emergence of generic formulations present opportunities.

FAQs

What is the current market size of meloxicam?

The meloxicam market was valued at USD 2.8 billion in 2023[1].

What is the projected growth rate of the meloxicam market?

The market is expected to grow at a CAGR of 4.5% from 2024 to 2031 and around 5% from 2024 to 2036[1][4].

Which segment is expected to hold the largest revenue share in the meloxicam market?

The osteoarthritis segment is expected to account for the largest revenue share, approximately 40% by 2036[5].

What are the key drivers of the meloxicam market growth?

Key drivers include the increasing prevalence of arthritis, patient awareness, need for efficient pain management, and the availability of generic equivalents[1][4].

Which region is expected to account for the largest revenue share in the meloxicam market?

North America is anticipated to account for the largest revenue share, driven by a high incidence of arthritis and other chronic pain diseases[4].

Sources

1. Market Research Intellect: Meloxicam Drug Market Size, Share | Industry Research Report 2031
2. RxList: Mobic (Meloxicam): Side Effects, Uses, Dosage, Interactions, Warnings
3. Market Research Intellect: Global meloxicam market size and forecast - Market Research Intellect
4. Research Nester: Meloxicam Market Size - Global Forecast Report 2036
5. Research Nester: Meloxicam Market Analysis - Research Nester